MPAL patients (CD19-positive) with a positive MRD (>0.01%) by the end of 12 weeks had a worse EFS of 50% ± 19% compared to 83% ± 5.3% for the entire CD19-positive cohort treated with an ALL-like regimen [45]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.